meibomain gland disfunction
Conditions
Interventions
Group 1:Lipiflow treatment
Group 2:squeeze meibomain gland by manual
Sponsors
The Eye & ENT Hospital of Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: (1) patients aged 18 years old and more; (2) meet the diagnostic criteria of MGD: eyelid margin abnormality and meibomain gland secretion abnormality; (3) after subjects and their guardians fully understood with the contents of the study, they signed the informed consent to participate in this clinical trial voluntarily.
Exclusion criteria
Exclusion criteria: (1) patients with acute thrombus embolism have occurred recently (within 6 months), such as myocardial infarction or cerebrovascular events; (2) patients with anxiety and depression (anxiety, Depression score greater than 60); (3) sleep disorder (AIS score > 6); (4) pregnant or lactating women; (5) acute ocular inflammation or infection; (6) who are using lacrimal duct embolism The patients; (7) had obvious scar or keratosis on the eyelid margin; (8) received anyone of following surgeries within 6 months before entering the group: 1) ophthalmic surgery; 2) eyelid surgery; 3) LASIK operation; 4) neuroparalysis occurred in the treatment area; (9) tarsal gland atrophy more than two-thirds.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MG expressibility and quality; | — |
Secondary
| Measure | Time frame |
|---|---|
| OSDI score;Schirmer test;tear break up time; | — |
Countries
China
Contacts
Public ContactGong Lan
The Eye & ENT Hospital of Fudan University
Outcome results
None listed